-
VectorY Therapeutics Receives U.K. MHRA Authorization and EMA Approval to Initiate Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People Living with Amyotrophic Lateral Sclerosis (ALS)
April 28, 2026 The authorizations represent an expansion of the PIONEER-ALS clinical trial,currently enrolling participants at clinical trial sites in the U.S. VectorY Therapeutics, a leader in vectorized antibody therapies… More >>
-
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
April 30, 2026 87 percent reduction in risk of death compared to patients who received placebo (hazard ratio: 0.13, p-value: < 0.0001) Corcept Therapeutics, a commercial-stage company engaged in the… More >>
-
Novartis ASTRALS trial with VHB937 in ALS fully enrolled
Community Statement:Enrollment complete for Novartis Phase 2 (ASTRALS) Clinical Trial in amyotrophic lateral sclerosis (ALS) More >>
-
Community Update:First Participant Enrolled in the PREVAiLS Phase 3 ALS Study
March 30, 2026 Dear ALS community, We are delighted to share that a new global, pivotal Phase 3 clinical trial, called PREVAiLS, studying the investigational drug pridopidine, has enrolled its… More >>
-
Ferrer and Prilenia Announce First Participant Enrolled inthe “PREVAiLS” Phase 3 Study of Pridopidine in ALS
March 30, 2026 PREVAiLS is a pivotal, global, 500-participant Phase 3 study to evaluate efficacy and safety of pridopidine, an investigational drug, in slowing ALS progression (ALSFRS-R) in early, rapidly… More >>
-
Additional Phase 2 Data of AL-S Pharma Lead Program with AP-101 in ALS
March 19 2026 Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS Results supported by key neuroaxonal injury… More >>
-
Results from the PARADIGM Phase 2b clinical trial of PrimeC in ALS have been published
March 17, 2026 NeuroSense announces that results from the PARADIGM Phase 2b clinical trial of PrimeC in ALS have been published in the prestigious journal JAMA Neurology. The article presents… More >>
-
Argenx statement to the ALS community
February 27, 2026 Update on adimanebart Phase 2a reALISe study in people living with ALS Today, argenx shares an important update on the adimanebart Phase 2a reALISe study in people… More >>
